Press Resease

Antithrombin Market - Global Industry Analysis

Antithrombin Market by Source (Human and Goat Milk), Application (Diagnostics, Therapeutics, and Research), By Dosage Form (Liquid and Lyophilized): Global Industry Perspective, Comprehensive Analysis and Forecast, 2020 – 2028.

Published Date: 23-May-2021 Category: Pharmaceutical Report Format : PDF Pages: 132 Report Code: ZMR-2514 Status : Published

The global Antithrombin market accounted for USD 543.0 Million in 2020 and is expected to reach USD 820.8 Million by 2028, growing at a CAGR of 5.3% from 2021 to 2028.

Description

Market Overview    

The global Antithrombin market accounted for USD 543.0 Million in 2020 and is expected to reach USD 820.8 Million by 2028, growing at a CAGR of 5.3% from 2021 to 2028.     

Antithrombin is a protein present in the blood stream, which functions as a naturally occurring mild blood thinner. Antithrombin helps to control too much clotting. A person with low antithrombin levels has more tendency to clot more easily. Vice-versa, if antithrombin levels are too high, a person could, theoretically, have a more bleeding tendency. However, raised levels of antithrombin do not appear to cause bleeding or have any clinical significance.

Antithrombin is a serpin which is similar in structure to most other plasma protease inhibitors. According to the report published by U.S. Department of health & human services in 2018, Antithrombin deficiency is expected to occur in about 1 in 2000 people across the globe.

COVID-19 Impact Analysis:

The Covid-19 has positively impacted on the growth of the Antithrombin market. As the Antithrombin is a protein which helps to regulate blood clot formation. Due to corona virus spread in the community, the protein level and immunity of the people drop due to severe attack of virus. In order to increase the protein level, the Antithrombin plays important role prevention of blood clotting as it acts as a natural blood thinner and extensively used while performing surgical procedures in the patient with low antithrombic levels. However, the world markets are slowly opening to their full potential and theirs a surge in demand of Antithrombin is likely to increase in the coming years. The market would remain bullish in upcoming year.   

Growth Factors

The widespread use of antithrombin for the treatment of various medical conditions such as extracorporeal membrane oxygenation, hereditary antithrombin deficiency, sepsis, and disseminated intravascular coagulation are the major factors responsible for the growth of global antithrombin market. Moreover, the rising adoption of antithrombin as a combination therapy with heparin is expected to open huge growth opportunities for antithrombin market.

Report Scope: 

Report Attribute Details
Base Year 2020
Historic Years 2016 - 2020
Forecast Years 2021 - 2028
Segments Covered By Product Type, By Application, and By End Use
Forecast Units Value (USD Billion), and Volume (Units)
Quantitative Units Revenue in USD million/billion and CAGR from 2021 to 2028
Regions Covered North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World
Countries Covered U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others
Number of Companies Covered 10 companies with scope for including additional 15 companies upon request
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.
Customization Scope Avail customized purchase options to meet your exact research needs.

Source Segment Analysis Preview

By source, the antithrombin market has been segmented as human, and goat milk. The human source, the segment is estimated to account major shares in global antithrombin market in 2016. Humans are the major source of antithrombins, but know a day’s the use of goat milk for the production of antithrombin is increasing. Goats produce about 800 liters of milk per year. As compared to cell culture model, the yield of the active protein by goat model is 10 times more. The transgenic goats are the excellent source for antithrombin production, as they produce plenty of milk in short generation time, and these factors are responsible for the high growth of goat milk segment over the forecast period. Currently, the goat milk produced antithrombins are available in developed countries such as U.S., UK, and Germany etc. The increasing adoption of newer technologies and advanced products in developing countries is expected to drive the growth of segment over the forecast period.

On the basis of application, the global antithrombin market is segmented into major three types such as diagnostics, therapeutics, and research. By application, the therapeutics segment is estimated to account major share in global antithrombin market. The increasing research and development activities and rising government initiatives for research are expected to drive the growth of research segment globally.

On the basis of the dosage form, the global antithrombin market is segmented as a liquid and lyophilized. The lyophilized dosage form accounted major share in the global market in 2016 and expected to register high CAGR. Lyophilized antithrombins have good self-life, easy to handle and, have wide application and these factors are expected to propel the growth of segment over the forecast period.

Key Market Players & Competitive Landscape

Some of the key players in global Antithrombin market include Grifols, rEVO Biologics Inc., Shire plc., Kedrion S.p.A., CSL Limited, Scripps Laboratories Inc., and Lee Biosolutions among others.

The global Antithrombin market is segmented as follows:   

By Source

  • Human
  • Goat Milk

By Application

  • Diagnostics
  • Therapeutics
  • Research

By Dosage Form

  • Liquid
  • Lyophilized

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

  • Chapter No. 1 Introduction
    • 1.1. Report Description
      • 1.1.1. Purpose of the Report
      • 1.1.2. USP & Key Offerings
    • 1.2. Key Benefits for Stakehulders
    • 1.3. Target Audience
    • 1.4. Report Scope
  • Chapter No. 2 Executive Summary
    • 2.1. Key Findings
      • 2.1.1. Top Investment Pockets
        • 2.1.1.1. Market Attractiveness Analysis, By Source
        • 2.1.1.2. Market Attractiveness Analysis, By Application
        • 2.1.1.3. Market Attractiveness Analysis, By Dosage Form
        • 2.1.1.4. Market Attractiveness Analysis, By Region
    • 2.2. Market Snapshot
    • 2.3. Global Antithrombin Market, 2016 – 2028 (USD Million)
    • 2.4. Insights from Primary Respondents
  • Chapter No. 3 COVID 19 Impact Analysis
    • 3.1. Impact Assessment of COVID-19 Pandemic, By Region
      • 3.1.1. North America
      • 3.1.2. Europe
      • 3.1.3. Asia Pacific
      • 3.1.4. Latin America
      • 3.1.5. The Middle-East and Africa
    • 3.2. Quarterly Market Revenue and Forecast by Region 2020 & 2021
    • 3.3. Pre COVID-19 Market Revenue, By Region, 2016-2019 (USD Million)
    • 3.4. Post COVID-19 Market Revenue, By Region, 2020-2028 (USD Million)
    • 3.5. Key Strategies Undertaken by Companies to Tackle COVID-19
      • 3.5.1. Company Quarterly Revenue Analysis, 2019 & 2020
    • 3.6. Short Term Dynamics
    • 3.7. Long Term Dynamics
  • Chapter No. 4 Antithrombin Market – Source Segment Analysis
    • 4.1. Overview
      • 4.1.1. Market Revenue Share, By Source, 2020 & 2028
    • 4.2. Human
      • 4.2.1. Market Size and Forecast, By Region (USD Million)
      • 4.2.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.2.3. Key Market Trends, Growth Factors, & Opportunities
    • 4.3. Goat Milk
      • 4.3.1. Market Size and Forecast, By Region (USD Million)
      • 4.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.3.3. Key Market Trends, Growth Factors, & Opportunities
  • Chapter No. 5 Antithrombin Market – Application Segment Analysis
    • 5.1. Overview
      • 5.1.1. Market Revenue Share, By Application, 2020 & 2028
    • 5.2. Diagnostics
      • 5.2.1. Market Size and Forecast, By Region (USD Million)
      • 5.2.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 5.2.3. Key Market Trends, Growth Factors, & Opportunities
    • 5.3. Therapeutics
      • 5.3.1. Market Size and Forecast, By Region (USD Million)
      • 5.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 5.3.3. Key Market Trends, Growth Factors, & Opportunities
    • 5.4. Research
      • 5.4.1. Market Size and Forecast, By Region (USD Million)
      • 5.4.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 5.4.3. Key Market Trends, Growth Factors, & Opportunities
  • Chapter No. 6 Antithrombin Market – Dosage Form Segment Analysis
    • 6.1. Overview
      • 6.1.1. Market Revenue Share, By Dosage Form, 2020 & 2028
    • 6.2. Liquid
      • 6.2.1. Market Size and Forecast, By Region (USD Million)
      • 6.2.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 6.2.3. Key Market Trends, Growth Factors, & Opportunities
    • 6.3. Lyophilized
      • 6.3.1. Market Size and Forecast, By Region (USD Million)
      • 6.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 6.3.3. Key Market Trends, Growth Factors, & Opportunities
  • Chapter No. 7 Antithrombin Market – Regional Analysis
    • 7.1. Overview
      • 7.1.1. Global Market Revenue Share, By Region, 2020 & 2028
      • 7.1.2. Global Market Revenue, By Region, 2016 – 2028 (USD Million)
    • 7.2. North America
      • 7.2.1. North America Market Revenue, By Country, 2016 – 2028 (USD Million)
      • 7.2.2. North America Market Revenue, By Source, 2016 – 2028
      • 7.2.3. North America Market Revenue, By Application, 2016 – 2028
      • 7.2.4. North America Market Revenue, By Dosage Form, 2016 – 2028
      • 7.2.5. U.S.
        • 7.2.5.1. U.S. Market Revenue, By Source, 2016 – 2028
        • 7.2.5.2. U.S. Market Revenue, By Application, 2016 – 2028
        • 7.2.5.3. U.S. Market Revenue, By Dosage Form, 2016 – 2028
      • 7.2.6. Canada
        • 7.2.6.1. Canada Market Revenue, By Source, 2016 – 2028
        • 7.2.6.2. Canada Market Revenue, By Application, 2016 – 2028
        • 7.2.6.3. Canada Market Revenue, By Dosage Form, 2016 – 2028
      • 7.2.7. Mexico
        • 7.2.7.1. Mexico Market Revenue, By Source, 2016 – 2028
        • 7.2.7.2. Mexico Market Revenue, By Application, 2016 – 2028
        • 7.2.7.3. Mexico Market Revenue, By Dosage Form, 2016 – 2028
    • 7.3. Europe
      • 7.3.1. Europe Market Revenue, By Country, 2016 – 2028 (USD Million)
      • 7.3.2. Europe Market Revenue, By Source, 2016 – 2028
      • 7.3.3. Europe Market Revenue, By Application, 2016 – 2028
      • 7.3.4. Europe Market Revenue, By Dosage Form, 2016 – 2028
      • 7.3.5. Germany
        • 7.3.5.1. Germany Market Revenue, By Source, 2016 – 2028
        • 7.3.5.2. Germany Market Revenue, By Application, 2016 – 2028
        • 7.3.5.3. Germany Market Revenue, By Dosage Form, 2016 – 2028
      • 7.3.6. France
        • 7.3.6.1. France Market Revenue, By Source, 2016 – 2028
        • 7.3.6.2. France Market Revenue, By Application, 2016 – 2028
        • 7.3.6.3. France Market Revenue, By Dosage Form, 2016 – 2028
      • 7.3.7. U.K.
        • 7.3.7.1. U.K. Market Revenue, By Source, 2016 – 2028
        • 7.3.7.2. U.K. Market Revenue, By Application, 2016 – 2028
        • 7.3.7.3. U.K. Market Revenue, By Dosage Form, 2016 – 2028
      • 7.3.8. Italy
        • 7.3.8.1. Italy Market Revenue, By Source, 2016 – 2028
        • 7.3.8.2. Italy Market Revenue, By Application, 2016 – 2028
        • 7.3.8.3. Italy Market Revenue, By Dosage Form, 2016 – 2028
      • 7.3.9. Spain
        • 7.3.9.1. Spain Market Revenue, By Source, 2016 – 2028
        • 7.3.9.2. Spain Market Revenue, By Application, 2016 – 2028
        • 7.3.9.3. Spain Market Revenue, By Dosage Form, 2016 – 2028
      • 7.3.10. Rest of Europe
        • 7.3.10.1. Rest of Europe Market Revenue, By Source, 2016 – 2028
        • 7.3.10.2. Rest of Europe Market Revenue, By Application, 2016 – 2028
        • 7.3.10.3. Rest of Europe Market Revenue, By Dosage Form, 2016 – 2028
    • 7.4. Asia Pacific
      • 7.4.1. Asia Pacific Market Revenue, By Country, 2016 – 2028 (USD Million)
      • 7.4.2. Asia Pacific Market Revenue, By Source, 2016 – 2028
      • 7.4.3. Asia Pacific Market Revenue, By Application, 2016 – 2028
      • 7.4.4. Asia Pacific Market Revenue, By Dosage Form, 2016 – 2028
      • 7.4.5. China
        • 7.4.5.1. China Market Revenue, By Source, 2016 – 2028
        • 7.4.5.2. China Market Revenue, By Application, 2016 – 2028
        • 7.4.5.3. China Market Revenue, By Dosage Form, 2016 – 2028
      • 7.4.6. Japan
        • 7.4.6.1. Japan Market Revenue, By Source, 2016 – 2028
        • 7.4.6.2. Japan Market Revenue, By Application, 2016 – 2028
        • 7.4.6.3. Japan Market Revenue, By Dosage Form, 2016 – 2028
      • 7.4.7. India
        • 7.4.7.1. India Market Revenue, By Source, 2016 – 2028
        • 7.4.7.2. India Market Revenue, By Application, 2016 – 2028
        • 7.4.7.3. India Market Revenue, By Dosage Form, 2016 – 2028
      • 7.4.8. South Korea
        • 7.4.8.1. South Korea Market Revenue, By Source, 2016 – 2028
        • 7.4.8.2. South Korea Market Revenue, By Application, 2016 – 2028
        • 7.4.8.3. South Korea Market Revenue, By Dosage Form, 2016 – 2028
      • 7.4.9. South-East Asia
        • 7.4.9.1. South-East Asia Market Revenue, By Source, 2016 – 2028
        • 7.4.9.2. South-East Asia Market Revenue, By Application, 2016 – 2028
        • 7.4.9.3. South-East Asia Market Revenue, By Dosage Form, 2016 – 2028
      • 7.4.10. Rest of Asia Pacific
        • 7.4.10.1. Rest of Asia Pacific Market Revenue, By Source, 2016 – 2028
        • 7.4.10.2. Rest of Asia Pacific Market Revenue, By Application, 2016 – 2028
        • 7.4.10.3. Rest of Asia Pacific Market Revenue, By Dosage Form, 2016 – 2028
    • 7.5. Latin America
      • 7.5.1. Latin America Market Revenue, By Country, 2016 – 2028 (USD Million)
      • 7.5.2. Latin America Market Revenue, By Source, 2016 – 2028
      • 7.5.3. Latin America Market Revenue, By Application, 2016 – 2028
      • 7.5.4. Latin America Market Revenue, By Dosage Form, 2016 – 2028
      • 7.5.5. Brazil
        • 7.5.5.1. Brazil Market Revenue, By Source, 2016 – 2028
        • 7.5.5.2. Brazil Market Revenue, By Application, 2016 – 2028
        • 7.5.5.3. Brazil Market Revenue, By Dosage Form, 2016 – 2028
      • 7.5.6. Argentina
        • 7.5.6.1. Argentina Market Revenue, By Source, 2016 – 2028
        • 7.5.6.2. Argentina Market Revenue, By Application, 2016 – 2028
        • 7.5.6.3. Argentina Market Revenue, By Dosage Form, 2016 – 2028
      • 7.5.7. Rest of Latin America
        • 7.5.7.1. Rest of Latin America Market Revenue, By Source, 2016 – 2028
        • 7.5.7.2. Rest of Latin America Market Revenue, By Application, 2016 – 2028
        • 7.5.7.3. Rest of Latin America Market Revenue, By Dosage Form, 2016 – 2028
    • 7.6. The Middle-East and Africa
      • 7.6.1. The Middle-East and Africa Market Revenue, By Country, 2016 – 2028 (USD Million)
      • 7.6.2. The Middle-East and Africa Market Revenue, By Source, 2016 – 2028
      • 7.6.3. The Middle-East and Africa Market Revenue, By Application, 2016 – 2028
      • 7.6.4. The Middle-East and Africa Market Revenue, By Dosage Form, 2016 – 2028
      • 7.6.5. GCC Countries
        • 7.6.5.1. GCC Countries Market Revenue, By Source, 2016 – 2028
        • 7.6.5.2. GCC Countries Market Revenue, By Application, 2016 – 2028
        • 7.6.5.3. GCC Countries Market Revenue, By Dosage Form, 2016 – 2028
      • 7.6.6. South Africa
        • 7.6.6.1. South Africa Market Revenue, By Source, 2016 – 2028
        • 7.6.6.2. South Africa Market Revenue, By Application, 2016 – 2028
        • 7.6.6.3. South Africa Market Revenue, By Dosage Form, 2016 – 2028
      • 7.6.7. Rest of Middle-East Africa
        • 7.6.7.1. Rest of Middle-East Africa Market Revenue, By Source, 2016 – 2028
        • 7.6.7.2. Rest of Middle-East Africa Market Revenue, By Application, 2016 – 2028
        • 7.6.7.3. Rest of Middle-East Africa Market Revenue, By Dosage Form, 2016 – 2028
  • Chapter No. 8 Antithrombin Market – Industry Analysis
    • 8.1. Introduction
    • 8.2. Market Drivers
      • 8.2.1. Driving Factor 1 Analysis
      • 8.2.2. Driving Factor 2 Analysis
    • 8.3. Market Restraints
      • 8.3.1. Restraining Factor Analysis
    • 8.4. Market Opportunities
      • 8.4.1. Market Opportunity Analysis
    • 8.5. Porter’s Five Forces Analysis
    • 8.6. PEST Analysis
    • 8.7. Regulatory Landscape
    • 8.8. Source Landscape
    • 8.9. Regional Market Trends
      • 8.9.1. North America
      • 8.9.2. Europe
      • 8.9.3. Asia Pacific
      • 8.9.4. Latin America
      • 8.9.5. The Middle-East and Africa
    • 8.10. Pricing Analysis
    • 8.11. Value Chain Analysis
    • 8.12. Downstream Buyers
    • 8.13. Distributors/Traders List
  • Chapter No. 9 Competitive Landscape
    • 9.1. Company Market Share Analysis – 2019
      • 9.1.1. Global Antithrombin Market: Company Market Share, 2019
      • 9.1.2. Global Antithrombin Market, Company Market Revenue, 2016 – 2019 (USD Million)
      • 9.1.3. Global Antithrombin Market, Company Y-o-Y Growth, 2017 – 2019 (%)
      • 9.1.4. Global Antithrombin Market: Radar Determinant Chart, 2019
    • 9.2. Strategic Developments
      • 9.2.1. Acquisitions & Mergers
      • 9.2.2. New Product Launch
      • 9.2.3. Regional Expansion
    • 9.3. Company Strategic Developments – Heat Map Analysis
  • Chapter No. 10 Company Profiles
    • 10.1. Grifuls
      • 10.1.1. Company Overview
      • 10.1.2. Key Executives
      • 10.1.3. Product Portfolio
      • 10.1.4. Financial Overview
      • 10.1.5. Operating Business Segments
      • 10.1.6. Business Performance
      • 10.1.7. Recent Developments
    • 10.2. rEVO Biulogics Inc
    • 10.3. Shire plc
    • 10.4. Kedrion S.p.A
    • 10.5. CSL Limited
    • 10.6. Scripps Laboratories Inc
    • 10.7. Lee Biosulutions
    • 10.8. Company 8
    • 10.9. Company 9
    • 10.10. Company 10
  • Chapter No. 11 Marketing Strategy Analysis
    • 11.1. Marketing Channel
    • 11.2. Direct Marketing
    • 11.3. Indirect Marketing
    • 11.4. Marketing Channel Development Trends
    • 11.5. Economic/Pulitical Application Change
  • Chapter No. 12 Research Methodology
    • 12.1. Research Methodology
    • 12.2. Phase I - Secondary Research
    • 12.3. Phase II - Data Modeling
      • 12.3.1. Company Share Analysis Model
      • 12.3.2. Revenue Based Modeling
    • 12.4. Phase III - Primary Research
    • 12.5. Research Limitations
      • 12.5.1. Assumptions

List of Figures 

FIG NO. 1. Market Attractiveness Analysis, By Source
FIG NO. 2. Market Attractiveness Analysis, By Application
FIG NO. 4. Market Attractiveness Analysis, By Region
FIG NO. 5. Global Antithrombin Market Revenue, 2016 – 2028 (USD Million)
FIG NO. 6. Impact of COVID-19 Pandemic in North America Countries
FIG NO. 7. Market Revenue Share, By Source, 2020 & 2028
FIG NO. 8. Global Antithrombin Market for Human, Revenue (USD Million) 2016 – 2028
FIG NO. 9. Comparative Revenue Analysis of Antithrombin Market for Human, By Country, 2020 & 2028
FIG NO. 10. Global Antithrombin Market for Goat Milk, Revenue (USD Million) 2016 – 2028
FIG NO. 11. Comparative Revenue Analysis of Antithrombin Market for Goat Milk, By Country, 2020 & 2028
FIG NO. 12. Market Revenue Share, By Application, 2020 & 2028
FIG NO. 13. Global Antithrombin Market for Diagnostics, Revenue (USD Million) 2016 – 2028
FIG NO. 14. Comparative Revenue Analysis of Antithrombin Market for Diagnostics, By Country, 2020 & 2028
FIG NO. 15. Global Antithrombin Market for Therapeutics, Revenue (USD Million) 2016 – 2028
FIG NO. 16. Comparative Revenue Analysis of Antithrombin Market for Therapeutics, By Country, 2020 & 2028
FIG NO. 17. Global Antithrombin Market for Research, Revenue (USD Million) 2016 – 2028
FIG NO. 18. Comparative Revenue Analysis of Antithrombin Market for Research, By Country, 2020 & 2028
FIG NO. 19. Market Revenue Share, By Dosage Form, 2020 & 2028
FIG NO. 20. Global Antithrombin Market for Liquid, Revenue (USD Million) 2016 – 2028
FIG NO. 21. Comparative Revenue Analysis of Antithrombin Market for Liquid, By Country, 2020 & 2028
FIG NO. 22. Global Antithrombin Market for Lyophilized, Revenue (USD Million) 2016 – 2028
FIG NO. 23. Comparative Revenue Analysis of Antithrombin Market for Lyophilized, By Country, 2020 & 2028
FIG NO. 24. Global Antithrombin Market Revenue Share, By Region, 2020 & 2028
FIG NO. 25. North America Antithrombin Market Revenue, 2016 - 2028 (USD Million)
FIG NO. 26. Porter’s Five Forces Analysis for Global Antithrombin Market
FIG NO. 27. PEST Analysis for Global Antithrombin Market
FIG NO. 28. Pricing Analysis for Global Antithrombin Market
FIG NO. 29. Value Chain Analysis for Global Antithrombin Market
FIG NO. 30. Company Share Analysis, 2019
FIG NO. 31. Radar Determinant Chart, 2019
FIG NO. 32. Company Strategic Developments – Heat Map Analysis
FIG NO. 33. Grifols Business Segment Revenue Share, 2020 (%)
FIG NO. 34. Grifols Geographical Segment Revenue Share, 2020 (%)
FIG NO. 35. Market Channels
FIG NO. 36. Marketing Channel Development Trend
FIG NO. 37. Growth in World Gross Product, 2008-2018
FIG NO. 38. Research Methodology – Detailed View
FIG NO. 39. Research Methodology


List of Tables 

TABLE NO. 1. Global Antithrombin Market: Snapshot
TABLE NO. 2. Quarterly Antithrombin Market Revenue by Region, 2020
TABLE NO. 3. Quarterly Antithrombin Market Revenue Forecast by Region, 2021
TABLE NO. 4. Pre COVID-19 Market Revenue, By Region, 2016-2019 (USD Million)
TABLE NO. 5. Post COVID-19 Market Revenue, By Region, 2020-2028 (USD Million)
TABLE NO. 6. Global Antithrombin Market for Human, by Region, 2016 – 2028 (USD Million)
TABLE NO. 7. Global Antithrombin Market for Goat Milk, by Region, 2016 – 2028 (USD Million)
TABLE NO. 8. Global Antithrombin Market for Diagnostics, by Region, 2016 – 2028 (USD Million)
TABLE NO. 9. Global Antithrombin Market for Therapeutics, by Region, 2016 – 2028 (USD Million)
TABLE NO. 10. Global Antithrombin Market for Research, by Region, 2016 – 2028 (USD Million)
TABLE NO. 11. Global Antithrombin Market for Liquid, by Region, 2016 – 2028 (USD Million)
TABLE NO. 12. Global Antithrombin Market for Lyophilized, by Region, 2016 – 2028 (USD Million)
TABLE NO. 13. G6obal Antithrombin Market Revenue, By Region, 2016 – 2028 (USD Million)
TABLE NO. 14. North America Antithrombin Market Revenue, By Country, 2016 – 2028 (USD Million)
TABLE NO. 15. North America Antithrombin Market Revenue, By Source, 2016 – 2028 (USD Million)
TABLE NO. 16. North America Antithrombin Market Revenue, By Application, 2016 – 2028 (USD Million)
TABLE NO. 17. North America Antithrombin Market Revenue, By Dosage Form, 2016 – 2028 (USD Million)
TABLE NO. 18. U.S. Antithrombin Market Revenue, By Source, 2016 – 2028 (USD Million)
TABLE NO. 19. U.S. Antithrombin Market Revenue, By Application, 2016 – 2028 (USD Million)
TABLE NO. 20. U.S. Antithrombin Market Revenue, By Dosage Form, 2016 – 2028 (USD Million)
TABLE NO. 21. Canada Antithrombin Market Revenue, By Source, 2016 – 2028 (USD Million)
TABLE NO. 22. Canada Antithrombin Market Revenue, By Application, 2016 – 2028 (USD Million)
TABLE NO. 23. Canada Antithrombin Market Revenue, By Dosage Form, 2016 – 2028 (USD Million)
TABLE NO. 24. Mexico Antithrombin Market Revenue, By Source, 2016 – 2028 (USD Million) 
TABLE NO. 25. Mexico Antithrombin Market Revenue, By Application, 2016 – 2028 (USD Million)
TABLE NO. 26. Mexico Antithrombin Market Revenue, By Dosage Form, 2016 – 2028 (USD Million)
TABLE NO. 27. Drivers for the Antithrombin Market: Impact Analysis
TABLE NO. 28. Restraints for the Antithrombin Market: Impact Analysis
TABLE NO. 29. Major Buyers of Antithrombin 
TABLE NO. 30. Distributors/Traders List of Antithrombin 
TABLE NO. 31. Global Antithrombin Market, Company Market Revenue, 2016 – 2019 (USD Million)
TABLE NO. 32. Global Antithrombin Market, Company Y-o-Y Growth, 2017 – 2019 (USD Million)
 
 

Methodology

This report is based on in-depth qualitative and quantitative analyses of the global Antithrombin market. Zion Research has collected and analyzed key data belong to the global Antithrombin market using a variety of methods. Quantitative analysis has been done following various projection and sampling techniques.

The qualitative analysis involved primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes were validated through experts' opinions. The market dynamics have been determined after conducting a detailed study of the micro and macroeconomic indicators of the market.

Various parameters have been taken into account, while estimating market size. The revenue generated by the leading industry participants in from the sales of Antithrombin across the world has been calculated through primary and secondary research.

Zion Research employs the combination of secondary research followed by extensive primary research. Under secondary research, we refer to prominent paid as well as open access data sources including product literature, company annual reports, government publications, press releases, industry association’s magazines and other relevant sources for data collection. Other prominent secondary sources include STATISTA, trade journals, trade associations, statistical data from government websites, etc. 

For this study, Zion Research has conducted all-encompassing primary research with key industry participants to collect first had data. Moreover, in-depth interviews with key opinion leaders also assisted in validation of findings from secondary research and to understand key trends in the Antithrombin industry. Primary research makes up the major source of data collection and validation.   

Primary Research

We conduct primary interviews with industry participants and commentators on an ongoing basis to validate data and analysis. A typical research interview fulfills the following functions:

  • Provides firsthand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
  • Helps in validating and strengthening the secondary research findings
  • Further, develops the analysis team’s expertise and market understanding
  • Primary research involves e-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies

Participants who typically participate in such a process include, but are not limited to:

  • Industry participants: CEOs, VPs, marketing/product managers, market intelligence managers and national sales managers
  • Purchasing managers, technical personnel, distributors and resellers
  • Outside experts: Investment bankers, valuation experts and research analysts specializing in specific markets

Key opinion leaders specializing in different areas corresponding to different industry verticals

Secondary Research

Secondary research sources that are typically referred to include, but are not limited to:

  • Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
  • IDC and other relevant magazines
  • Internal and external proprietary databases, and relevant patent and regulatory databases
  • National government documents, statistical databases and market reports

News articles, press releases and webcasts specific to companies operating in the market

Following a comprehensive secondary and primary research and insights thus gathered, analysts at Zion Research have provided an in-depth analysis of various aspects of the Antithrombin market.

Models

Where no hard data is available, we use models and estimates to produce comprehensive data sets. A rigorous methodology is adopted, wherein the available hard data is cross-referenced with the following data types to produce estimates:

  • Demographic data: Population split by segments
  • Macroeconomic indicators: GDP, PPP, Per Capita Income, etc.
  • Industry indicators: Expenditure, technology stage and infrastructure, sector growth and facilities
  • Data is then cross-checked by an expert panel.

Free Analysis

Antithrombin is a protein present in the blood stream, which functions as a naturally occurring mild blood thinner. It helps to prevent too much clotting. By inactivating the blood clotting protein thrombin, it blocks the blood clotting mechanism; hence it is known as anti-thrombin. There are two major causes of antithrombin deficiency (AT), inherited or genetic antithrombin deficiency, and acquired antithrombin deficiency. An inherited or genetic deficiency occurred due to a genetic mutation or abnormality, and an acquired deficiency due to some other disease such as liver failure, nephrotic syndrome, metastatic tumors, severe trauma etc.

The global antithrombin market is segmented on the basis of source, application, dosage form, and geographically. Based on the source, the antithrombin market has been segmented as human, and goat milk. The human source segment accounted major shares in 2016. The goat source segment is expected to register high CAGR over the forecast period. The increasing adoption of goat milk for the production of antithrombin is expected to propel the growth of segment over the forecast period. The goat milk derived antithrombin is currently available in Europe and North America. However, the availability of these products in other regions such as Asia Pacific, Middle East & Africa is projected to drive the market share of goat milk source segment over the forecast period.

Global-Antithrombin-Market.png

By Application, the global antithrombin market is segmented as diagnostics, therapeutics, and research. The therapeutics segment is accounted major share in 2016 in global antithrombin market. Availability of therapeutic antithrombin preparation globally with approved indications is the major factor contributing growth of the segment. Moreover, increasing research activities is expected to boost the growth of segment over the forecast period.

By dosage form, the global antithrombin market is segmented as a liquid and lyophilized. The lyophilized segment accounted major share in global antithrombin market in 2016 by dosage form. The lyophilized dosage form has long expiry date and they are widely available. The limited application of liquid antithrombins in research accounts for low market share for the segment. 

By region, the global antithrombin market is segmented into five major regions, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Europe is expected to remain the dominant region over the forecast period. Early availability of advanced technologies, rising adoption of antithrombin therapies owing to high awareness are the major factors contributing towards the growth of the market in Europe.  North America was the second largest market followed by the Asia Pacific. Asia Pacific market is projected to grow at the highest rate during the forecast period owing to increasing healthcare budgets, and extensive research initiatives in the region. The Middle East and Africa, and Latin America are also expected to experience moderate growth in the years to come.

Some of the key players in global Antithrombin market include Grifols, rEVO Biologics Inc., Shire plc., Kedrion S.p.A., CSL Limited, Scripps Laboratories Inc., and Lee Biosolutions among others. The rising demand for recombinant antithrombins and increasing competition among key players are expected to drive the growth of the market over the forecast period.

Choose License Type

Request the coronavirus impact analysis across industries and markets

FrequentlyAsked Questions

The global Antithrombin market was valued at USD 543 Million in 2020.

The global Antithrombin market is expected to reach USD 820.8 Million by 2028, growing at a CAGR of 5.3% between 2021 to 2028.

Some of the key factors driving the global Antithrombin market growth are Increasing Number of Surgical Procedures and Technological Advancement.

Europe is anticipated to remain the leading region over the forecast period. The rising adoption of antithrombin therapies owing to high awareness in the region is expected to boost the growth of the market in Europe.

The key dominant player’s operative in global Antithrombin market Grifols, rEVO Biologics Inc., Shire plc., Kedrion S.p.A., CSL Limited, Scripps Laboratories Inc., and Lee Biosolutions among others.  

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (844) 845-5245
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1 (844) 845-5245
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed